Treatment of Psoriatic Arthritis
Psoriatic arthritis is inflammatory arthritis affecting some people with psoriasis. It causes joint pain, stiffness and swelling ranging from mild to severe with potential for joint damage.
Psoriatic arthritis is inflammatory arthritis affecting some people with psoriasis. It causes joint pain, stiffness and swelling ranging from mild to severe with potential for joint damage.
First-Line Treatment Principles
- ✓Treat-to-target (T2T) strategy in RA and SpA: aim for remission or low disease activity
- ✓Disease-modifying antirheumatic drugs (DMARDs) initiated early in RA — methotrexate first-line
- ✓Biologic DMARDs (anti-TNF, anti-IL-6, JAK inhibitors) when csDMARD inadequate
- ✓Hydroxychloroquine and low-dose prednisolone for SLE; immunosuppressives for organ-threatening disease
- ✓Analgesia stepped approach: paracetamol → NSAIDs → opioids (short-term); topical agents in OA
Medications Used in Psoriatic Arthritis
Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Upadacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Filgotinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Non-Pharmacological Management
- •Physical therapy: joint protection, range-of-motion exercises, strengthening — essential in OA and RA
- •Weight management: reduces mechanical load on hips/knees; reduces systemic inflammation
- •Occupational therapy: joint protection aids, assistive devices, workplace adaptations
- •Hydrotherapy and aquatic exercise: low-impact joint rehabilitation in OA
- •Dietary: Mediterranean diet reduces RA disease activity; omega-3 supplementation may reduce inflammation
- •Smoking cessation: major independent risk factor for RA initiation and worse disease course
- •Sun protection in SLE (UV can trigger flares)
Treatment Goals
Monitoring Parameters
- ◆Disease activity scores: DAS28 (RA), BASDAI/ASDAS (SpA), SLEDAI (lupus) — at 1, 3, 6 months
- ◆Shared care monitoring for methotrexate: FBC, LFTs monthly × 6, then every 3 months
- ◆Anti-TNF monitoring: TB screening (IGRA) before initiation; LTBI prophylaxis if positive
- ◆Bone mineral density: DEXA scan at baseline and every 2 years on long-term corticosteroids
- ◆Anti-dsDNA and complement (C3/C4) in SLE flare surveillance
- ◆Opthalmology: hydroxychloroquine retinopathy screening annually after 5 years use
Escalation Criteria
- →Inadequate response to methotrexate at 3 months → add hydroxychloroquine/sulfasalazine or switch to biologic
- →Lupus nephritis → high-dose prednisolone + mycophenolate or cyclophosphamide
- →Vasculitis with organ involvement → IV methylprednisolone + cyclophosphamide or rituximab
- →Septic arthritis: urgent joint aspiration + IV antibiotics; surgical washout if joint destruction
Special Populations
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →